Our primary focus will be on elucidating the metabolic and molecular links between diabetes and Alzheimer’s disease and assessing the potential role of antidiabetic drugs including GLP-1 analogs, SGLT2 inhibitors, and DPP4 inhibitors, in the context of Alzheimer’s disease. Here, SLC5A2 is linked to early-onset autosomal dominant Alzheimer disease.